Amicus Therapeutics Inc
NASDAQ:FOLD
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
9.04
14.52
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Amicus Therapeutics Inc
Wall Street
Price Targets
FOLD Price Targets Summary
Amicus Therapeutics Inc
According to Wall Street analysts, the average 1-year price target for
FOLD
is 18.11 USD
with a low forecast of 14.14 USD and a high forecast of 22.05 USD.
FOLD Last Price Targets
Amicus Therapeutics Inc
The latest public price target was made on Oct 17, 2024 by
Tazeen Ahmad
from
Bank of America Securities
,
who expects
FOLD
stock to
rise by 53%
over the next 12 months.
You can read more about this price target by viewing
the article on StreetInsider.
| Analyst | Price Target | Date | Article |
|---|---|---|---|
Tazeen Ahmad
Bank of America Securities
|
15
USD
Upside 53% |
2 months ago
Oct 17, 2024
|
Amicus Therapeutics (FOLD) PT Raised to $15 at BofA Securities
StreetInsider
|
Debjit Chattopadhyay
Guggenheim
|
13
USD
Upside 33% |
7 months ago
May 14, 2024
|
Amicus upgraded to Buy from Neutral at Guggenheim
TheFly
|
Jeffrey Hung
Morgan Stanley
|
19
USD
Upside 94% |
7 months ago
May 9, 2024
|
Amicus Therapeutics (FOLD) PT Lowered to $19 at Morgan Stanley
StreetInsider
|
|
Jeffrey Hung
Morgan Stanley
|
20
USD
Upside 104% |
1 year ago
Dec 19, 2023
|
Morgan Stanley Upgrades Amicus Therapeutics (FOLD) to Overweight
StreetInsider
|
Price Targets
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.
What is FOLD's stock price target?
Price Target
18.11
USD
According to Wall Street analysts, the average 1-year price target for
FOLD
is 18.11 USD
with a low forecast of 14.14 USD and a high forecast of 22.05 USD.
What is Amicus Therapeutics Inc's Revenue forecast?
Projected CAGR
25%
The
compound annual growth rate
of Amicus Therapeutics Inc's revenue for the next 4 years is
25%.
You don't have any saved screeners yet
